2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-168340
    COX-2/15-LOX-IN-6
    COX-2/15-LOX-IN-6 (Compound 5l) is the dual inhibitor for COX-2 and 15-LOX, with IC50 of 0.201 μM and 11.723 μM. COX-2/15-LOX-IN-6 inhibits the expression of PGE, TNF-α, IL-6 and iNOS in serum, and exhibits anti-inflammatory effect in Carrageenan (HY-125474)-induced rats edema model.
    COX-2/15-LOX-IN-6
  • HY-168341
    sGC activator 2
    sGC activator 2 (Compound 16a) is an activator for soluble guanylate cyclase (sGC), that promotes the cGMP production and exhibits vascular protective and anti-inflammatory activities.
    sGC activator 2
  • HY-168344
    CACPD2011a-0001278239 1030781-08-8
    CACPD2011a-0001278239 is a β2AR mixed agonist that shows a wide range of high-affinity binding to both wild-type and T164I β2AR variants, with no cytotoxicity or mutagenicity, making it suitable for asthma research.
    CACPD2011a-0001278239
  • HY-168376
    9(10)-Nitrooleate 1092676-99-7
    9(10)-Nitrooleate (9(10)-Nitrated oleic acid) is a nitrated derivative of Oleic acid (HY-N1446). 9(10)-Nitrooleate can activate PPAR (PPARα, PPARβ/δ, and PPARγ), promoting fat formation and glucose uptake, inhibiting the function of neutrophils and platelets, and can be used in lipid metabolism and inflammation research.
    9(10)-Nitrooleate
  • HY-168466
    Anti-neuroinflammation agent 2 3040102-76-6
    Anti-neuroinflammation agent 2 (compound 4) demonstrates anti-neuroinflammatory and antibacterial activities, with IC50 values of 3.06 µM for TNF-α and 4.31 µM for IL-6, alongside EC50 values ranging from 0.87 to 3.16 µM against Gram-positive bacteria.
    Anti-neuroinflammation agent 2
  • HY-168471
    AAL-149 177258-60-5
    AAL-149 is a FTY720 (HY-12005) analog and TRPM7 inhibitor (IC50 = 1.081 μM) with multimodal anti-inflammatory effects and without targeting S1P receptors. AAL-149 can be utilized in anti-inflammatory research.
    AAL-149
  • HY-168474
    P2X4 antagonist-4
    P2X4 antagonist-4 (compound 64) is a potent P2X4R antagonist with an IC50 value of 8 µM. P2X4 antagonist-4 blocks the ATP-induced NLRP3 inflammasome activation and release of IL-1β.
    P2X4 antagonist-4
  • HY-168484
    T-10430
    T-10430 is a potent and orally active leukotriene B4 receptor 2 (BLT2) agonist. T-10430 has the potential for the research of psoriasis.
    T-10430
  • HY-168498
    GJG057 2761767-18-2
    GJG057 is a selective, orally active inhibitor for leukotriene C4 synthase (LTC4S) with an IC50 of 44 nM. GJG057 exhibits anti-inflammatory activity in mouse skin inflammation model and mouse asthma model.
    GJG057
  • HY-168501
    Neuroprotective agent 6
    Neuroprotective Agent 6 (Compound Y12) is a neuroprotective agent with antioxidant activity and capabilities in DPPH, ABTS radical scavenging. Neuroprotective Agent 6 demonstrates superior neuroprotective effects in both cellular models induced by oxygen-glucose deprivation/reoxygenation (OGD/R) and animal models induced by transient middle cerebral artery occlusion (tMCAO). Additionally, Neuroprotective Agent 6 exhibits significant metal chelating activity towards Cu2+.
    Neuroprotective agent 6
  • HY-168503
    NLRP3-IN-54
    NLRP3-IN-54 (Compound C4) is an NLRP3 inhibitor. NLRP3-IN-54 can significantly reduce the levels of active Caspase-1 and active IL-1β (IC50 = 0.805 μM), can be used for inflammation research.
    NLRP3-IN-54
  • HY-168521
    αvβ6-IN-1
    αvβ6-IN-1 (compound 28) is a potent and orally active αvβ6 integrin inhibitor with a pIC50 value of 8.1. αvβ6-IN-1 has the potential for the research of idiopathic pulmonary fibrosis.
    αvβ6-IN-1
  • HY-168522
    αvβ6-IN-2
    αvβ6-IN-2 (compound 20) is a potent and orally active αvβ6 integrin inhibitor with a pIC50 value of 7.8. αvβ6-IN-2 has the potential for the research of idiopathic pulmonary fibrosis.
    αvβ6-IN-2
  • HY-168526
    Keap1-Nrf2-IN-24
    Keap1-Nrf2-IN-24 (compound 57) is a potent Keap1-Nrf2 inhibitor with a Ki value of 13 nM. Keap1-Nrf2-IN-24 increases the protein expression of TRXR1 and NQO1. Keap1-Nrf2-IN-24 increases the AKR1B10 mRNA expression. Keap1-Nrf2-IN-24 shows good metabolic stability.
    Keap1-Nrf2-IN-24
  • HY-168532
    ST2-IN-1
    ST2-IN-1 (compound 31) is a Stimulation-2 (ST2) inhibitor, with an IC50 value of 7 μM in AlphaLISA assay, and 7.19 μM in HEK-Blue assay. ST2-IN-1 effectively attenuats the ST2/IL-33 signaling in human mast cells.
    ST2-IN-1
  • HY-168554
    STING-IN-10
    STING-IN-10 (P8) is a dual STING PROTAC degrader and inhibitor with a DC50 value of 2.58 μM in THP-1 cells. STING-IN-10 has anti-inflammatory activity.(Pink: Target protein ligand (HY-168676); Black: linker (HY-W123015); Blue: E3 ligase ligand (HY-126457))
    STING-IN-10
  • HY-168558
    PDE4B/D-IN-4
    PDE4B/D-IN-4 (compound 4p) is a potent inhibitor of PDE-4B and PDE-4D, with IC50s of 5.50 nM and 6.81 nM, respectively. PDE4B/D-IN-4 shows an increase in the level of intracellular cAMP.
    PDE4B/D-IN-4
  • HY-168567
    RIPK2-IN-6 2242432-02-4
    RIPK2-IN-6 (Compound 15a) is an inhibitor for RIPK, that inhibits the phosphorylation of RIPK2, and thus inhibits the NF-κB and MAPK signaling pathways. RIPK2-IN-6 exhibits anti-inflammatory and anti-fibrotic activities in Dextran sodium sulfate (HY-116282C)-induced mice colitis models.
    RIPK2-IN-6
  • HY-168624
    VAV1 degrader-2 3050683-29-6
    VAV1 degrader-2 (Example 176) is a molecular glue degrader based on targeting VAV 1 with a DC50 of 4.41 nM. VAV1 degrader-2 can be used in the study of inflammatory and autoimmune diseases.
    VAV1 degrader-2
  • HY-168650
    ROCK/HDAC-IN-1
    ROCK/HDAC-IN-1 (Compound 10h) is an orally active ROCK/HDAC inhibitor. ROCK/HDAC-IN-1 inhibits ROCK1/2 (IC50: 254.9 nM, 58.18 nM) and HDAC1/2/3/6/8 (IC50: 9.09, 8.03, 6.26, 0.41, 7.69 nM). ROCK/HDAC-IN-1 stimulates the activation of DAMPs, specifically Calreticulin (CRT) exposure and HMGB1 release, indicating that it is a potential ICD inducer.. ROCK/HDAC-IN-1 has antiproliferative activity against breast cancer cells (IC50: 0.37 μM for MDA-MB-231 cell), and inhibits tumor growth and activates T cells without apparent toxicity.
    ROCK/HDAC-IN-1
Cat. No. Product Name / Synonyms Application Reactivity